Deep within the root bark of the central African shrub Tabernanthe iboga lies ibogaine, its most active mind-altering compound . Researchers first extracted this unique alkaloid back in 1901, kicking off over a hundred years of quiet scientific fascination.
It behaves like a master key in the brain, binding to a vast web of receptors. This unusual pharmacology has made it a focal point for researchers looking to disrupt dependency cycles, unpack deep psychological trauma, and facilitate profound spiritual quests.
| Parameter | Value / Description |
|---|---|
| Chemical Identifier | Ibogaine |
| IUPAC Designation | 12-Methoxyibogamine |
| Formula | C₂₀H₂₆N₂O |
| Molecular Mass | 310.43 g/mol |
| CAS Registry | 83-74-9 |
| Physical State | Pale or snowy crystalline powder (as HCl salt) |
| Solubility Profile | Dissolves readily in water and pure ethanol (as HCl salt) |
For laboratory testing, scientists rely almost exclusively on ibogaine hydrochloride (HCl) engineered to a purity of ≥98%.
1901 — French researchers successfully extract and isolate the alkaloid from the raw plant for the first time.
1939 — French pharmacies begin selling Lambarene, an iboga-derived stimulant and mood elevator.
1960s — Early psychotherapists test the compound as an experimental tool to unlock deep-seated memories.
1962 — While experimenting with the drug recreationally, Howard Lotsof accidentally discovers its ability to block heroin withdrawal .
1990s — Present — A global network of underground and legal clinics emerges. Meanwhile, independent researchers keep digging into the molecule’s unique power to halt severe chemical dependencies .
2024 — Stanford scientists publish a landmark paper in Nature Medicine, showing that the drug might help repair neurological damage in combat veterans suffering from brain trauma.
This molecule does not play by the usual rules. Instead of targeting one specific area, it acts like a shotgun blast across the central nervous system :
| Target Pathway | Neurological Activity |
|---|---|
| Dopamine | Alters pleasure and reward pathways |
| Serotonin | Blocks the serotonin transporter (SERT) to boost mood chemicals |
| Nicotinic | Binds to nicotinic acetylcholine sites |
| GABA | Tunes down overactive signaling to ease anxiety |
| Muscarinic | Engages acetylcholine receptors to influence memory and dreaming |
Primary Pathways:
Processing and Breakdown:
Your liver processes the substance slowly, using the CYP2D6 enzyme to convert it into a long-lasting compound called noribogaine. Because everyone’s genetics are different, some people process this enzyme much slower than others, which can spike the drug’s concentration in the blood and trigger dangerous heart complications .
Breaking the Cycle of Dependence:
At a deep neurological level, the drug has shown an uncanny ability to instantly quiet physical withdrawal and silence intense cravings.
Observed Outcomes:
Tested Substances:
Inner Work and Spiritual Journeys:
Its applications stretch far beyond detox, serving as a catalyst for:
⚠️ VITAL SAFETY WARNING
This compound is not gentle on the heart. It can drastically slow down the heart’s electrical recharging cycle—a state called QTc prolongation—which sometimes triggers a lethal, erratic heartbeat known as Torsades des Pointes.
Primary Dangers:
Who Should Avoid It:
Official Public Health Warnings:
Health authorities at the Dutch RIVM explicitly warn the public against consuming this compound, citing a high probability of unpredictable and fatal heart rhythm disruptions.
Dutch Regulations:
The substance is not banned by the Dutch Opium Act. Even so, it holds no official status as an approved medication under local drug laws, meaning it cannot legally be marketed, prescribed, or sold to treat medical conditions .
Worldwide Status:
Legal landscapes differ wildly across borders. Get in touch with our team directly, and we can help you figure out if we can securely and discreetly ship to your specific location.
| Core Topic | Quick Facts |
|---|---|
| Identity | The primary active alkaloid extracted from Tabernanthe iboga |
| Key Dates | First isolated in 1901; its ability to halt cravings was discovered in 1962 |
| Brain Interaction | Alters dopamine, serotonin, nicotine, GABA, and muscarinic pathways |
| Primary Uses | Breaking severe chemical addictions and exploring deep psychological states |
| Main Hazard | Severe heart toxicity (especially extended QTc intervals) which can lead to death |
| Dutch Status | Allowed under the Opium Act, but lacks registration as a legal therapeutic drug |